Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$877M |
| 2 |
Booking.com
BKNG
|
+$370M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$329M |
| 4 |
Boeing
BA
|
+$303M |
| 5 |
Walmart Inc
WMT
|
+$291M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$544M |
| 2 |
iShares MBS ETF
MBB
|
+$461M |
| 3 |
NVIDIA
NVDA
|
+$452M |
| 4 |
T-Mobile US
TMUS
|
+$426M |
| 5 |
Apple
AAPL
|
+$408M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 3.15% |
| 2 | Healthcare | 3.06% |
| 3 | Financials | 2.35% |
| 4 | Consumer Discretionary | 2.28% |
| 5 | Industrials | 1.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Bio-Rad Laboratories Class A
BIO
$9.53B
| $19M | ﹤0.01% |
29,441
+25,831
| +716% | +$15.7M |
|
2052
PUT
Unilever
UL
$134B
| $19M | ﹤0.01% |
288,089
+22,133
| +8% | +$1.47M |
|
2053
PUT
iShares Core S&P 500 ETF
IVV
$908B
| $19M | ﹤0.01% |
44,100
+14,400
| +48% | +$6.03M |
|
2054
Air Products & Chemicals
APD
$68.8B
| $18.9M | ﹤0.01% |
65,827
+26,443
| +67% | +$7.76M |
|
2055
Medtronic
MDT
$117B
| $18.9M | ﹤0.01% |
152,245
-2,802,561
| -95% | -$352M |
|
|
ZNGA
2056
CALL
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $18.9M | ﹤0.01% |
1,777,000
-137,600
| -7% | -$1.45M |
|
2057
CALL
Sprout Social
SPT
$599M
| $18.9M | ﹤0.01% |
211,200
+89,800
| +74% | +$6.22M |
|
|
APGB.U
2058
DELISTED
Apollo Strategic Growth Capital II Units, each consisting of one Class A ordinary share, and one-fifth of one warrant
APGB.U
| $18.9M | ﹤0.01% |
1,888,284
-110,595
| -6% | -$1.11M |
|
2059
CALL
Monster Beverage
MNST
$91.7B
| $18.8M | ﹤0.01% |
825,200
+214,400
| +35% | +$5.03M |
|
2060
Apollo Global Management
APO
$83.1B
| $18.8M | ﹤0.01% |
302,478
-1,048,463
| -78% | -$58.1M |
|
|
COOP
2061
DELISTED
Mr. Cooper
COOP
| $18.8M | ﹤0.01% |
568,933
+331,501
| +140% | +$11.1M |
|
2062
Viavi Solutions
VIAV
$10.7B
| $18.8M | ﹤0.01% |
1,062,666
-1,294,606
| -55% | -$21.8M |
|
2063
CALL
Editas Medicine
EDIT
$433M
| $18.8M | ﹤0.01% |
331,300
-43,400
| -12% | -$1.6M |
|
|
ABMD
2064
PUT
DELISTED
Abiomed Inc
ABMD
| $18.7M | ﹤0.01% |
60,000
+1,200
| +2% | +$368K |
|
|
AVAN
2065
DELISTED
Avanti Acquisition Corp.
AVAN
| $18.7M | ﹤0.01% |
1,919,724
-64,516
| -3% | -$634K |
|
2066
First Trust Enhanced Short Maturity ETF
FTSM
$6.54B
| $18.7M | ﹤0.01% |
311,794
-42,507
| -12% | -$2.55M |
|
|
CERN
2067
PUT
DELISTED
Cerner Corp
CERN
| $18.7M | ﹤0.01% |
239,100
+133,000
| +125% | +$10.2M |
|
2068
Franco-Nevada
FNV
$45.2B
| $18.7M | ﹤0.01% |
128,703
+100,799
| +361% | +$14.6M |
|
|
NVO
2069
Novo Nordisk
NVO
$201B
| $18.6M | ﹤0.01% |
444,958
-8,970
| -2% | -$348K |
|
2070
CALL
KE Holdings
BEKE
$18.8B
| $18.6M | ﹤0.01% |
390,600
+116,000
| +42% | +$5.93M |
|
2071
CALL
Copart
CPRT
$29.3B
| $18.6M | ﹤0.01% |
564,800
+290,000
| +106% | +$8.99M |
|
2072
Diageo
DEO
$53.1B
| $18.6M | ﹤0.01% |
97,006
-67,021
| -41% | -$12.5M |
|
|
SFIX
2073
Stitch Fix
SFIX
$479M
| $18.6M | ﹤0.01% |
308,305
+69,778
| +29% | +$3.57M |
|
2074
PUT
F5
FFIV
$22.8B
| $18.6M | ﹤0.01% |
99,500
+24,100
| +32% | +$4.64M |
|
2075
PUT
Appian
APPN
$2.54B
| $18.6M | ﹤0.01% |
134,800
+13,400
| +11% | +$1.52M |
|
Similar funds
Ken Griffin's Q2 2021 Portfolio in Review
As of Q2 2021, Ken Griffin held 15,073 positions worth $447B, up 9.6% from $408B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Ken Griffin's Q2 2021 filing shows 1,965 new, 5,545 increased, 5,814 reduced and 1,500 closed positions. Its largest new stake was Coinbase: 1,010,057 shares worth $256M. The largest sale was Microsoft, an estimated $544M.
By sector, the portfolio is most concentrated in Technology at 3.2% of assets, down from 3.9% a quarter earlier, followed by Healthcare and Financials.
- Ken Griffin's largest Q2 2021 buy was Coinbase: 1,010,057 shares worth $256M.
- Ken Griffin added most to AT&T in Q2 2021, an estimated $877M increase.
- Ken Griffin's biggest Q2 2021 reduction was Microsoft, cutting an estimated $544M.
- Ken Griffin fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $197M.
- Ken Griffin's ten largest holdings make up 27% of its $447B portfolio in Q2 2021.
- Ken Griffin opened 1,965 new positions and closed 1,500 in Q2 2021.
- Ken Griffin's portfolio value rose 9.6% quarter-over-quarter to $447B.
Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.